**Supplementary Data**

# **β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer**

Annika Eurola1, Ari Ristimäki2,3, Harri Mustonen1, Anna-Maria Nurmi1, Jaana Hagström2,4,5, Pauliina Kallio5, Kari Alitalo5, Caj Haglund\*1,5 and Hanna Seppänen\*1,5

1Department of Surgery, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

2Department of Pathology, HUSLAB, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

3Applied Tumor Genomics (ATG), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland

4Department of Oral Pathology and Radiology, University of Turku, Turku, Finland

5Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki

\*Shared equal last authorship

Supplementary Table. Different neoadjuvant therapy regimens used.

|  |
| --- |
| gemcitabine-cisplatin 3-6 cycles |
| FOLFIRINOX 3-9 cycles |
| gemcitabine + chemoradiotherapy 50.4 Gy |
| gemcitabine-cisplatin 3-7 cycles + chemoradiotherapy (capecitabine or gemcitabine) 50.4 Gy - 60 Gy |
| singe-gemcitabine 3-8 cycles |
| gemcitabine-nab-paclitaxel 5 cycles |
| gemcitabine-capecitabine 4-5 cycles |
| Radiotherapy 50.4 Gy |
| singe-gemcitabine + radiotherapy 50.4 Gy + gemcitabine-nab-paclitaxel |
| FOLFIRINOX + gemcitabine-cisplatin + chemoradiotherapy 50.4 Gy |
| cisplatin-gemcitabine-capecitabine |
| FOLFIRINOX 3 cycles + gemcitabine-nab-paclitaxel 3 cycles |
| FOLFIRINOX 5 cycles + radiotherapy 50.4 Gy |